A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial

  1. Gonzalez Martin, A.
  2. Sanchez Lorenzo, L.
  3. Colombo, N.
  4. Depont Christensen, R.
  5. Heitz, F.
  6. Meirovitz, M.
  7. Selle, F.
  8. Van Gorp, T.
  9. Alvarez, N.
  10. Sanchez, J.
  11. Marqués, C.
Journal:
International Journal of Gynecological Cancer

ISSN: 1525-1438 1048-891X

Year of publication: 2021

Volume: 31

Issue: 4

Pages: 617-622

Type: Article

DOI: 10.1136/IJGC-2020-001633 GOOGLE SCHOLAR

Sustainable development goals